Pancreatic cancerKRASG12CKRAS inhibitorKRASG12C inhibitorsPROTACsKRAS vaccineKirsten Rat Sarcoma (KRAS) is a master oncogene involved in cellular proliferation and survival and is the most commonly mutated oncogene in all cancers. Activating KRAS mutations are present in over 90% of pancreatic ductal...
"KRAS-G12R is unique in that it is a mutation that seems to only occur in pancreatic cancer and not in the other cancer types associated with KRAS mutations, such as lung cancer," said Dr. Chandwani, who is also a member of the Sandra and Edward Meyer Cancer Center and the Englander ...
235,236]. Furthermore, PDAC cells have been shown to express high levels of survivin. Exosomes containing survivin can induce tumour resistance and provide an additional advantage for tumour progression. Research has indicated that KRAS-dependent cancer cells produce exosomes rich in survivin,...
GENETIC mutationONCOGENESSEQUENCE analysisGENETICSKRAS is not simply mutated or wild type in pancreatic ductal adenocarcinoma (PDAC); actually, it has never been. More than 90% of PDACs carry mutated KRAS alleles; however, the impact on PDAC biology may vary with the tumor...
Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer. Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the ...
The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients with PDAC (42% with metastatic disease) at MD Anderson Cancer Center. Overall survival
T. Pancreatic cancer. Lancet 395, 2008–2020 (2020). Article PubMed CAS Google Scholar Luo, J. KRAS mutation in pancreatic cancer. Semin. Oncol. 48, 10–18 (2021). Article PubMed CAS PubMed Central Google Scholar Li, S. et al. Angiogenesis in pancreatic cancer: Current research ...
O'Bryan was recently awarded a grant by the Department of Defense to work on delivering monobodies into the lungs as potential therapies, and he is working with Aaron Hobbs, Ph.D., a fellow Hollings scientist, whose research focuses on KRAS(G12R) in pancreatic cancer. More information: Pad...
There are four major driver genes for pancreatic cancer:KRAS, CDKN2A, TP53, andSMAD4. KRASmutation and alterations inCDKN2Aare early events in pancreatic tumorigenesis. Endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration offer high diagnostic ability for pancreatic cancer....
In addition to KRAS mutation and RNF43 loss, downregulation of major histocompatibility complex class I (MHC-I) contributes to immune evasion and immunotherapy resistance due to impaired antigen presentation. Kimmelman and colleagues132demonstrated that in pancreatic cancer cells, an autophagy-dependent me...